11 results
8-K
EX-99.1
GUTS
Fractyl Health Inc.
24 Jun 24
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
6:04am
weight,1 2 yet they are not providing patients with sustained solutions to these chronic problems. Discontinuation rates are high due … century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies
10-Q
2024 Q1
GUTS
Fractyl Health Inc.
13 May 24
Quarterly report
4:06pm
type 2 diabetes (“T2D”) and obesity. The Company’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable
8-K
EX-99.1
GUTS
Fractyl Health Inc.
13 May 24
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
4:01pm
century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies … diabetes without the burden of chronic therapies. These statements are neither promises nor guarantees, but involve known and unknown risks
10-K
2023 FY
GUTS
Fractyl Health Inc.
1 Apr 24
Annual report
7:15am
glucose and body weight, all attributable to medicines requiring chronic administration, none of which modifies underlying disease progression. Highly … chronic symptom management to disease-modifying therapies that target the organ-level root causes of metabolic disease. The following table
8-K
EX-99.1
GUTS
Fractyl Health Inc.
1 Apr 24
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:10am
of chronic therapies. We are thrilled to announce today the approval of our IDE for Revita’s Remain-1 study in patients with obesity who wish to discontinue … , a single administration of GLP-1 PGTx resulted in 27% total body weight loss at day 28, compared to 21% loss for chronic semaglutide. Animals that were
8-K
EX-99.1
5i4i5xer a4qzf9zl
1 Apr 24
Regulation FD Disclosure
6:09am
424B4
wkmaazcjpbr7aewy0
2 Feb 24
Prospectus supplement with pricing info
4:18pm
S-1/A
huqzws4e ge
29 Jan 24
IPO registration (amended)
6:09am
S-1
e58fzur
14 Dec 23
IPO registration
3:39pm
DRS/A
cj4vw2euha1
21 Sep 23
Draft registration statement (amended)
12:00am
DRS/A
6mv52c
22 Aug 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next